Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents

Vaccine

Volumn 21, Issue 23, 2003, Pages 3169-3178

  Ben Yehuda, Arie ^a   Joseph, Aviva ^b   Barenholz, Yechezkel ^b   Zeira, Evelyne ^b   Even Chen, Simcha ^b   Louria Hayon, Igal ^b   Babai, Ilan ^b   Zakay Rones, Zichria ^b   Greenbaum, Evgenia ^b   Galprin, Ilia ^c   Glück, Reinhard ^d   Zurbriggen, Rinaldo ^d   Kedar, Eli ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d Berna Biotech   (Switzerland)

Author keywords

Elderly; IL 2; Influenza vaccine; Liposomes

Indexed keywords

ANTIBODY; HEMAGGLUTININ; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; LIPOSOMAL ANTIGEN; PHOSPHOLIPID ANTIBODY; RECOMBINANT INTERLEUKIN 2; SIALIDASE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA; KIDNEY DYSFUNCTION; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; NURSING HOME; PAIN; PLEURISY; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; VIRION;

EID: 12444343718     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00251-2     Document Type: Article

References (41)

1. Barker W.H., Mullooly J.P. Impact of epidemic-type A influenza in a defined adult population. Am. J. Epidemiol. 112:1980;798-811.
2. Couch R.B., Kasel J.A. Immunity to influenza in man. Annu. Rev. Microbiol. 37:1983;529-549.
3. Kilbourne ED, Arden NH. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: Saunders; 1999. p. 531-51.
4. Kilbourne E.D., Johansson B.E., Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 87:1990;786-790.
5. Nichol K.L., Margolis K.L., Wuorenma J., Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 331:1994;778-784.
6. Nichol K.L., Wuorenma J., von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch. Int. Med. 158:1998;1769-1776.
7. Effros R.B., Walford R.L. The immune response of aged mice to influenza: diminished T cell proliferation. Cell. Immunol. 81:1983;298-305.
8. Miller R.A. The aging immune system: primer and prospectus. Science. 273:1996;70-74.
9. Gregoriadis G. Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment. Immunomethods. 4:1994;210-216.
10. Gluck R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine. 10:1992;915-919.
11. Mbawuike I.N., Wyde P.R., Anderson P.M. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine. 8:1990;347-352.
12. Lachman L.B., Shih L.C., Rao X.M., Hu X., Bucana C.D., Ullrich S.E.et al. Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. AIDS Res. Hum. Retroviruses. 11:1995;921-932.
13. Kedar E, Barenholz Y. Delivery of cytokines by liposomes: a means of improving their immunomodulatory and anti-tumor activity. In: Chouaib S, editor. The biotherapy of cancers: from immunotherapy to gene therapy. Paris: INSERM; 1998. p. 333-62.
14. Babai I., Samira S., Barenholz Y., Zakay-Rones Z., Kedar E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine. 17:1999;1223-1238.
15. Babai I., Samira S., Barenholz Y., Zakay-Rones Z., Kedar E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Vaccine. 17:1999;1239-1250.
16. Babai I., Barenholz Y., Zakay-Rones Z., Greenbaum E., Samira S., Hayon I.et al. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin/neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine. 20:2001;505-515.
17. Ben-Yehuda A., Joseph A., Zeira E., Even-Chen S., Louria-Hayon I., Babai I.et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J. Med. Virol. 69:2003;560-567.
18. Barenholz Y, Amselem S. Liposome preparation and related techniques. In: Gregoriadis G, editor. Liposome technology, vol. 1. 2nd ed. Boca Raton, FL: CRC Press; 1993. p. 527-616.
19. Kedar E., Rutkowski Y., Braun E., Emanuel N., Barenholz Y. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J. Immunother. 16:1994;47-59.
20. Bishara A., Kedar E., Leshem B., Rosenkovitch E., Brautbar C. A short human and mouse MLR assay utilizing lymphokine (IL-2, IL-3) secretion as an early activation event. Transplantation. 51:1991;1104-1109.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
22. Peterson G.L. Determination of total protein. Meth. Enzymol. 91:1983;95-119.
23. Simberg D., Hirsch-Lerner D., Nissim R., Barenholz Y. Comparison of different commercially available cationic lipid-based transfection kits. J. Liposome Res. 10:2000;1-13.
24. Sever J. Application of microtechnique to viral serologic investigation. J. Immunol. 88:1962;321-325.
25. Gluck R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 344:1994;160-163.
26. Luther P., Klett G.E., Weber S., Pechmann H., Bergmann K.C. The lectin neuraminidase inhibition test: a new method for the detection of antibodies to neuraminidase. J. Biol. Stand. 11:1983;115-121.
27. Aymard-Henry M., Coleman M.T., Dowdle W.R., Laver W.G., Schild G.C., Webster R.G. Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull. WHO. 48:1973;199-202.
28. Chen Z., Yoshikawa T., Kadowaki S., Hagiwara Y., Matsuo K., Asanuma H.et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus hemagglutinin, neuraminidase and nucleoprotein. J. Gen. Virol. 80:1999;2559-2564.
29. Rimmelzwaan G.F., Claas E.C., van Amerongen G., de Jong J.C., Osterhaus A.D. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine. 17:1999;1355-1358.
30. Hilbert A.K., Fritzsche U., Kissel T. Biodegradable microspheres containing influenza A vaccine: immune response in mice. Vaccine. 17:1999;1065-1073.
31. van Slooten M.L., Hayon I., Babai I., Zakay-Rones Z., Wagner E., Storm G.et al. Immunoadjuvant acity of interferon-γ-liposomes co-administered with influenza vaccines. Biochim. Biophys. Acta. 1531:2001;99-101.
32. Powers D.C. Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults. Mech. Ageing Dev. 93:1997;179-188.
33. Kunzel W., Glathe H., Engelmann H., Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine. 14:1996;1108-1110.
34. Provinciali M., DiStefano G., Colombo M., Della Croce F., Gandolfi M.C., Daghetta L.et al. Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects. Mech. Ageing Dev. 77:1994;75-82.
35. Minutello M., Senatore F., Cecchinelli G., Bianchi M., Adreani T., Podda A.et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF 59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine. 17:1999;99-104.
36. Johansson B.E., Kilbourne E.D. Programmed antigenic stimulation: kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus or neuraminidase vaccine. Vaccine. 9:1991;330-333.
37. Webster R.G., Reay P.A., Laver W.G. Protection against lethal influenza with neuraminidase. Virology. 164:1988;230-237.
38. Kilbourne E.D., Couch R.B., Kasel J.A., Keitel W.A., Cate T.R., Quarles J.H.et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine. 13:1995;1799-1803.
39. McElhaney J.E., Meneilly G.S., Lechelt K.E., Beattie B.L., Bleackley R.C. Antibody response to whole-virus and split virus influenza vaccines in successful ageing. Vaccine. 11:1993;1055-1060.
40. Alving CR. Liposomes as adjuvants for vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New generation vaccines. 2nd ed. New York: Marcel Dekker; 1997. p. 207-13.
41. Levine J.S., Branch D.W., Rauch J. The anti-phospholipid syndrome. N. Engl. J. Med. 346:2002;752-763.